<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000350</url>
  </required_header>
  <id_info>
    <org_study_id>090942</org_study_id>
    <nct_id>NCT01000350</nct_id>
  </id_info>
  <brief_title>Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)</brief_title>
  <official_title>Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test whether an intravenous infusion of saline (salt water) will
      improve the exercise capacity in patients with postural tachycardia syndrome (POTS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in VO2max between saline day and placebo day</measure>
    <time_frame>Within 2 week</time_frame>
    <description>VO2max will be measured hours after saline and after placebo. The 2 interventions will be less than 2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity/Maximal Load (Watts) during peak VO2</measure>
    <time_frame>Less than 2 weeks</time_frame>
    <description>Maximal exercise load will be measured hours after saline and after placebo. The 2 interventions will be less than 2 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output between exercise tests (inert gas rebreathing technique)</measure>
    <time_frame>2-10 Days between exercise tests</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Exercise Post Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline infusion 1L hours before exercise test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given prior to exercise test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study</description>
    <arm_group_label>Exercise Post Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.9% saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo x1 lactose tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet diagnostic criteria of Postural Tachycardia Syndrome (POTS) 28

          -  Age between 18-65 years

          -  Male and female are eligible (although the majority of POTS patients are female).

          -  Able and willing to provide informed consent

        Exclusion Criteria:

          -  Presence of medical conditions that can explain postural tachycardia (e.g., acute
             dehydration, medications)

          -  Pregnancy

          -  Other factors which in the investigator's opinion would prevent the subject from
             completing the protocol.

          -  Patients who are bedridden or chair-ridden
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satish R Raj, MD MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mc.vanderbilt.edu/root/vumc.php?site=adc</url>
    <description>Vanderbilt Autonomic Dysfunction Center Website</description>
  </link>
  <reference>
    <citation>Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW, Robertson D. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005 Apr 5;111(13):1574-82. Epub 2005 Mar 21.</citation>
    <PMID>15781744</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Satish R. Raj</investigator_full_name>
    <investigator_title>Adjunct Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>orthostatic intolerance</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>tachycardia</keyword>
  <keyword>POTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

